[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645412":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":10,"locations":23,"responsibleParty":41,"collaborators":10,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":45,"sex":51,"minAge":52,"maxAge":10,"enrollmentInfo":53,"targetDuration":10,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":10,"overallStatus":25,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"AC Camargo Cancer Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Early Anti-PD1 Therapy Before Surgery",null,"Patients who initiated anti-PD1 therapy prior to surgery, based on routine clinical decision-making. Group classification is based on the timing of anti-PD1 therapy initiation in relation to surgical treatment.",[13],"Other: Anti-PD1 Therapy Timing",{"label":15,"type":10,"description":16,"interventionNames":17},"Standard Timing Group","Patients who underwent surgery followed by systemic\u002Fadjuvant anti-PD1 therapy according to standard clinical practice. Group classification is based on the timing of anti-PD1 therapy initiation in relation to surgical treatment.",[13],[19],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"Anti-PD1 Therapy Timing","This is an observational study variable. The timing of anti-PD1 therapy initiation in relation to surgery is determined by the treating physician as part of routine clinical practice. The study does not assign or modify any treatment.",[9,15],[24],{"facility":5,"status":25,"city":26,"state":26,"zip":10,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"RECRUITING","São Paulo","Brazil","BR",{"type":30,"coordinates":31},"Point",[32,33],-46.63611,-23.5475,{"lat":33,"lon":32},[36],{"name":37,"role":38,"phone":39,"phoneExt":10,"email":40},"MILTON SILVA","CONTACT","+55 11 99427-0884","milton.silva@accamargo.org.br",{"type":42,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100645412","neosent-early-anti-pd-1-therapy-in-high-risk-stage-ii-melanoma-100645412",false,"NCT07680699","NEOSENT: Early Anti-PD-1 Therapy In High-Risk Stage II Melanoma","NEOSENT - Early Anti-PD-1 Therapy In Patients With High-Risk Stage II Melanoma And\u002FOr Microsatellitosis: An Ambispective Observational Cohort Study","NEOSENT","Inclusion Criteria:\n\n\\- Adults (≥18 years) with histologically confirmed cutaneous melanoma stage IIB or IIC or stage III (N1c), managed in routine clinical practice.\n\nExclusion Criteria:\n\n* Patients without sufficient clinical or follow-up data.\n* Patients who do not provide informed consent (for prospective cohort).","ALL","18 Years",{"count":54,"type":55},250,"ESTIMATED","OBSERVATIONAL","This is an observational cohort study evaluating clinical and pathological outcomes in patients with high-risk stage II melanoma.\n\nPatients are included after receiving treatment as part of routine clinical practice. Decisions about treatment, including whether to start anti-PD1 therapy before surgery, are made by the treating physician and are not influenced by the study.\n\nThe study compares outcomes between patients who started anti-PD1 therapy before surgery and those treated according to the usual timing in clinical practice.\n\nNo treatments are assigned as part of the study.",[59],"Cutaneous Melanoma","2026-06-26",{"date":62,"type":63},"2026-07-02","ACTUAL",{"date":65,"type":63},"2025-04-23",{"date":67,"type":55},"2027-05",{"name":5,"class":6},1]